A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of MEDI5884 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2017
At a glance
- Drugs MEDI 5884 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 30 May 2017 Planned End Date changed from 1 Oct 2017 to 7 Sep 2017.
- 30 May 2017 Planned primary completion date changed from 1 Oct 2017 to 7 Sep 2017.
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.